AVE3085 Protects Coronary Endothelium from the Impairment of Asymmetric Dimethylarginine by Activation and Recoupling of eNOS
Publication in refereed journal

Times Cited
Web of Science7WOS source URL (as at 15/04/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractAsymmetric dimethylarginine (ADMA) is an endogenous inhibitor of eNOS and it is recognized as a risk factor for endothelial dysfunction in cardiovascular diseases. We investigated the effect of AVE3085, a newly developed transcription enhancer of eNOS, on ADMA-induced endothelial dysfunction in coronary arteries with underlying mechanisms explored.
All Author(s) ListXue HM, Yu CM, Underwood MJ, Huang JH, Yang Q
Journal nameCardiovascular Drugs and Therapy
Detailed descriptionTo ORKTS: DOI: 10.1007/s10557-012-6404-2
Volume Number26
Issue Number5
Pages383 - 392
LanguagesEnglish-United Kingdom
KeywordsCardiovascular diseases; Endothelium; Nitric oxide; Nitric oxide synthase; Oxidative stress
Web of Science Subject CategoriesCardiac & Cardiovascular Systems; CARDIAC & CARDIOVASCULAR SYSTEMS; Cardiovascular System & Cardiology; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

Last updated on 2021-15-04 at 23:54